l-carnitine: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
l-carnitine: clinical details
Prescribing considerations
- Confirm primary or secondary deficiency and maintain specialist metabolic oversight.
- Assess diabetes treatment because levocarnitine may improve glucose utilisation.
- Review severe renal impairment or dialysis status; prolonged oral use may allow trimethylamine metabolites to accumulate.
- Check for hereditary fructose intolerance and previous reactions to parahydroxybenzoates.
Contraindications and cautions
- Hypersensitivity to levocarnitine or an excipient.
- The selected sorbitol-containing product should not be used in hereditary fructose intolerance.
Monitoring
- Clinical and biochemical response.
- Free and acylcarnitine in plasma and urine.
- Blood glucose with insulin or other glucose-lowering treatment.
- INR or an appropriate coagulation test with coumarin anticoagulants.
- Gastrointestinal tolerance and body odour after treatment changes.
Clinical pharmacology
Only the L-isomer is biologically active. It supports mitochondrial transport and oxidation of long-chain fatty acids, buffers acyl-CoA availability and participates in pathways involving ketone bodies, glucose and branched-chain amino acids. Oral bioavailability is limited, and absorbed levocarnitine is distributed through blood to tissues.
Formulation and product differences
- The selected product is a clear, colourless-to-yellow oral solution supplied with a graduated pipette.
- It is labelled alcohol-free and sugar-free but contains sorbitol.
- It contains sodium methyl and propyl hydroxybenzoate preservatives, which can cause immediate or delayed hypersensitivity.
- Bottle sizes may vary and not all authorised packs are necessarily marketed.
l-carnitine preparations and strengths
Oral solution
Route: Oral
Strengths: 30%
l-carnitine interactions
Important recognised interactions and practical cautions include:
Warfarin, acenocoumarol and other coumarin anticoagulants
Levocarnitine has very rarely increased INR; coagulation monitoring should be intensified until stable.
Insulin and glucose-lowering tablets
Improved glucose use may contribute to hypoglycaemia, so glucose should be monitored and diabetes treatment reviewed when necessary.
Other oral products containing sorbitol or fructose
Combined exposure should be considered because this formulation contains sorbitol.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.